Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: inflammatory disease therapeutics - Degron Therapeutics

Next Previous
X
Search
Drug Profile

Research programme: inflammatory disease therapeutics - Degron Therapeutics

Latest Information Update: 24 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Degron Therapeutics; ShanghaiTech University
  • Developer Degron Therapeutics
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action CRBN protein modulators; Proteolysis
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Inflammation

Most Recent Events

  • 24 Jun 2022 Research programme: inflammatory disease therapeutics - Degron Therapeutics is available for licensing in World as of 24 Jun 2022. http://www.degrontx.com/en/
  • 19 Jun 2022 Early research in Inflammation in China (unspecified route) (Degron Therapeutics pipeline; 20 June 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top